This study focused on preventing the increased invasive migration of BRAFi‐R melanoma cells; however, our combined treatment with an IL‐6 antibody and Box5 also restored the sensitivity of these cells to the BRAF inhibitor PLX4032 (Fig. S7A–D). This evidence concerns the gene IL6 and melanoma.